Sugi Predict

Sugi Predict / Compounds / SCHEMBL20915064

SCHEMBL20915064

SCHEMBL20915064

CC(C)CN(Cc1cc(Cl)c2c(c1)OCCCO2)C(=O)C(C)CNCc1ccc(F)c(O)c1

nearest known ligand 0.62

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ PROKR2 Q8NFJ6 5/20 0.62
▸ MAPK8 P45983 1/20 0.34
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ HTT P42858 1/20 0.31
▸ HDAC4 P56524 1/20 0.31
▸ MEP1B Q16820 1/20 0.30
▸ PTGDR2 Q9Y5Y4 1/20 0.30
▸ DRD2 P14416 1/20 0.30
▸ DRD4 P21917 1/20 0.30
▸ DRD3 P35462 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL565529 0.91 PROKR2 (0.61) PROKR2MAPK8NPC1RAB9ASMN1; SMN2
SCHEMBL565649 0.90 PROKR2 (0.65) PROKR2MAPK8NPC1RAB9ASMN1; SMN2
SCHEMBL10106661 0.90 PROKR2 (0.65) PROKR2MAPK8NPC1RAB9ASMN1; SMN2
SCHEMBL565175 0.90 PROKR2 (0.62) PROKR2MAPK8SMN1; SMN2
SCHEMBL564319 0.88 PROKR2 (0.58) PROKR2MAPK8NPC1RAB9ASMN1; SMN2
SCHEMBL565634 0.88 PROKR2 (0.67) PROKR2MAPK8HTT
SCHEMBL564752 0.88 PROKR2 (0.68) PROKR2MAPK8
SCHEMBL10106655 0.87 PROKR2 (0.68) PROKR2MAPK8NPC1RAB9ASMN1; SMN2
SCHEMBL565783 0.87 PROKR2 (0.68) PROKR2MAPK8NPC1RAB9ASMN1; SMN2
SCHEMBL10107516 0.87 PROKR2 (0.68) PROKR2MAPK8NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10780095-B2 Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-09-22 — — US disclosed
US-10780095-B2 Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-09-22 — — US disclosed
US-20190117668-A1 COMPOSITIONS AND METHODS FOR TREATING DISORDERS OF CIRCADIAN AND DIURNAL RHYTHMS USING PROKINETICIN 2 AGONISTS AND ANTAGONISTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-04-25 — — US disclosed
US-20190117668-A1 COMPOSITIONS AND METHODS FOR TREATING DISORDERS OF CIRCADIAN AND DIURNAL RHYTHMS USING PROKINETICIN 2 AGONISTS AND ANTAGONISTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190117668-A1 COMPOSITIONS AND METHODS FOR TREATING DISORDERS OF CIRCADIAN AND DIURNAL RHYTHMS USING PROKINETICIN 2 AGONISTS AND ANTAGONISTS PER2, PROKR2, PROKR1 PROKR2 2/4885MAPK8 1861/4885NPC1 4117/4885
US-10780095-B2 Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists PER2, PROKR2, PROKR1 PROKR2 2/4885MAPK8 1861/4885NPC1 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.